Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lux Biosciences Inc.

www.luxbio.com

Latest From Lux Biosciences Inc.

Stockwatch: The Canadian patient

It has not been a good week for Canadian biotech. The sell-off of the crown jewels at QLT (scripintelligence.com, 25 September 2012), the return of rights to Cardiome (scripintelligence.com, 27 September 2012), the loss of a court case at Tekmira and the failure to receive fast-track NDA status at Aeterna Zentaris have left biotech investors north of the border wondering if there is much of a home-grown sector left.

Cardiovascular Immune Disorders

Isotechnika buoyed by deal with Vifor for voclosporin in lupus

Isotechnika's share price rose by 12.5% to Can$0.135 after the Canadian firm announced that it had licensed out its lead drug for a secondary indication. Vifor Pharma, the speciality pharma business of Swiss firm Galenica, has acquired rights to voclosporin for lupus and all proteinuric nephrology indications; Isotechnika is developing it primarily for the prevention of kidney transplant rejection.

Metabolic Disorders Gastrointestinal

The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind.

BioPharmaceutical Deals

The New Ophthalmic Drug Players

Unmet medical need and market size continue to drive venture investors to ophthalmic drug plays focused on diseases that blind. This interest is fueled by a stable pool of acquirers and the ability to in-license innovative, clinically validated compounds, providing VCs with a jump start to a potential exit.
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lux Biosciences Inc.
  • Senior Management
  • Dean Mitchell, Pres. & CEO
    Brett A Skolnik, CFO
    Eddy Anglade, MD, CMO
    Richard L Beckman, MD, SVP, Dev.
  • Contact Info
  • Lux Biosciences Inc.
    Phone: (201) 946-0551
    Harborside Financial Center Plaza 10
    14th Floor
    Jersey City, NJ 07302
    USA
UsernamePublicRestriction

Register